Neurogene Future Growth

Future criteria checks 2/6

Neurogene's earnings are forecast to decline at 32.5% per annum while its annual revenue is expected to grow at 78.7% per year. EPS is expected to decline by 27.2% per annum.

Key information

-32.5%

Earnings growth rate

-27.2%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate78.7%
Future return on equityn/a
Analyst coverage

Good

Last updated22 Aug 2024

Recent future growth updates

No updates

Recent updates

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Mar 26

Earnings and Revenue Growth Forecasts

NasdaqGM:NGNE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-112-81-894
12/31/2025N/A-89-75-796
12/31/20240-77-86-746
6/30/202412-67-66N/A
3/31/2024N/A9-60-60N/A
12/31/2023N/A14-52-51N/A
9/30/2023N/A-51-45-45N/A
6/30/2023N/A-49-44-44N/A
3/31/2023N/A-52-52-50N/A
12/31/2022N/A-55-55-53N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NGNE's earnings are forecast to decline over the next 3 years (-32.5% per year).

Earnings vs Market: NGNE's earnings are forecast to decline over the next 3 years (-32.5% per year).

High Growth Earnings: NGNE's earnings are forecast to decline over the next 3 years.

Revenue vs Market: NGNE's revenue (78.7% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: NGNE's revenue (78.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NGNE's Return on Equity is forecast to be high in 3 years time


Discover growth companies